Valneva SE (FRA:AYJ)
3.760
+0.036 (0.97%)
At close: Dec 30, 2025
Valneva SE Employees
Valneva SE had 713 employees as of December 31, 2024. The number of employees increased by 37 or 5.47% compared to the previous year.
Employees
713
Change (1Y)
37
Growth (1Y)
5.47%
Revenue / Employee
€252,331
Profits / Employee
€143,282
Market Cap
735.26M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 713 | 37 | 5.47% |
| Dec 31, 2023 | 676 | -43 | -5.98% |
| Dec 31, 2022 | 719 | -43 | -5.64% |
| Dec 31, 2021 | 762 | 262 | 52.40% |
| Dec 31, 2020 | 500 | -21 | -4.03% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Siemens Aktiengesellschaft | 317,562 |
| Deutsche Telekom AG | 198,194 |
| Mercedes-Benz Group AG | 175,264 |
| Bayerische Motoren Werke Aktiengesellschaft | 159,104 |
| Allianz SE | 156,626 |
| SAP SE | 109,121 |
| Siemens Energy AG | 98,995 |
| Deutsche Bank Aktiengesellschaft | 89,753 |
Valneva SE News
- 4 weeks ago - Valneva (VALN) Reveals Positive Phase 2 Data for Chikungunya Vaccine - GuruFocus
- 4 weeks ago - Valneva Reports Positive Final Phase 2 Antibody Persistence and Safety Results in Children for its Chikungunya Vaccine IXCHIQ - Wallstreet:Online
- 4 weeks ago - Valneva Reports Positive Final Phase 2 Antibody Persistence and Safety Results in Children for its Chikungunya Vaccine IXCHIQ® - GlobeNewsWire
- 5 weeks ago - VALNEVA Declaration of shares and voting rights: November 30, 2025 - GlobeNewsWire
- 6 weeks ago - Valneva Posts Positive Lyme Vaccine Booster Results — Pfizer Targeting 2026 Regulatory Filings - Benzinga
- 6 weeks ago - Valneva Posts Positive Lyme Vaccine Booster Results — Pfizer Targeting 2026 Regulatory Filings - Benzinga
- 6 weeks ago - Valneva to Further Consolidate its Operations in France - GlobeNewsWire
- 6 weeks ago - Valneva Shares Rise on Positive Data from Lyme Disease Vaccine Study - WSJ